MALE BREAST CANCER – CURRENT DIAGNOSTIC APPROACHES
نویسندگان
چکیده
منابع مشابه
Current management of male breast cancer.
Male breast cancer represent 1% of all male cancers. The authors, by a review of literature, analyze risk factors and genic mutations involved in the development of such cancer. They discuss instrumental procedures of diagnosis and screening, histologic features and surgical approach of male breast cancer. Furthermore, they suggest adjuvant therapies stressing the importance of an early diagnos...
متن کاملMale breast carcinoma: epidemiology, risk factors and current therapeutic approaches.
Male breast cancer is a very rare disease with an incidence of about 0.5-1% comparing with the one of female breast cancer but relatively little is known about its cause. Treatment strategies for breast cancer in males are derived from studies performed among females. The probable reasons behind the frequent, late diagnoses presented at stages III or IV might be the lack of awareness. The rarit...
متن کاملRadiotherapy of Bone Metastasis in Breast Cancer Patients - Current Approaches.
Bone metastases (BM) represent the most frequent indication for palliative radiotherapy in patients with breast cancer. BM increase the risk of skeletal-related events defined as pathological fractures, spinal cord compression, and, most frequently, bone pain. The therapeutic goals of palliative radiotherapy for BM are pain relief, recalcification, and stabilization, reducing spinal cord compre...
متن کاملCurrent approaches in treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest th...
متن کاملCurrent Approaches and Emerging Directions in HER2-resistant Breast Cancer
Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Romanian Journal of Clinical Research
سال: 2019
ISSN: 2602-0467
DOI: 10.33695/rjcr.v2i1.13